查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007879

微生物組療法市場預測至2034年—按產品類型、給藥途徑、技術、應用、最終用戶和地區分類的全球分析

Microbiome Therapeutics Market Forecasts to 2034 - Global Analysis By Product Type, Route of Administration, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球微生物組療法市場將達到 96 億美元，並在預測期內以 15.8% 的複合年成長率成長，到 2034 年達到 312 億美元。

微生物組療法是指透過調節人體微生物組的組成和功能來預防、治療或控制疾病的生物干預措施。人體微生物組是由多種微生物組成的複雜群落，棲息於腸道、皮膚、呼吸道以及身體其他部位。這些治療方法包括生物製藥產品、益生菌、益生元、合益素、糞便微生物移植。它們透過恢復微生物組生態系的平衡，來治療發炎性腸道疾病、困難梭狀桿菌感染疾病、代謝紊亂、腫瘤以及神經精神疾病。

腸道疾病盛行率增加

發炎性腸道疾病、大腸激躁症和困難梭狀桿菌感染疾病在全球範圍內的日益流行，是推動製藥企業投資以微生物組為基礎的治療方案的主要動力。儘管傳統的抗生素和免疫抑制療法有其局限性，仍無法滿足所有患者的需求，但基於微生物組的療法有望透過改變疾病進程而非僅僅抑制症狀來滿足這些需求。美國食品藥物管理局（FDA）對生物治療產品的核准框架日益成熟，加速了商業化研發管線的投資，並推動了針對主要消化器官系統和全身性疾病適應症的後期臨床試驗計畫。

製造業標準化的複雜性

生產標準化的複雜性構成了一項重大障礙。這是因為生物製藥和糞便微生物移植需要不同批次產品中微生物群落組成的一致性。目前的GMP框架和品管檢測體系仍在發展完善，以應對此一挑戰。在生產、製劑和低溫運輸配送過程中保持菌株活性，顯著增加了操作的複雜性。美國、歐洲和亞太地區在生物製藥產品分類方面的監管差異，造成了並行的申請負擔，對小規模的微生物治療研發公司造成了不成比例的影響。

腫瘤學中的微生物組調控

隨著越來越多的臨床證據顯示腸道菌叢的組成顯著影響癌症免疫療法的反應率和毒性特徵，腫瘤學領域的菌叢調控展現出突破性的商業性機會。旨在最佳化抗腫瘤免疫反應並與查核點抑制劑合併使用的生物治療產品已展現出令人矚目的早期臨床數據。製藥公司正與菌叢平台開發商進行策略合作，將菌叢調控納入黑色素瘤、肺癌和其他固體癌的癌症免疫通訊協定中，使其成為標準組成部分。

益生菌消費品競爭產品

來自消費級益生菌產品的價格競爭給臨床級微生物組療法帶來了報銷和市場定位的挑戰。這是因為醫生和患者可能認為市售益生菌補充劑與處方箋具有同等療效，但價格卻低得多。要將臨床級微生物組療法與普通保健產品區分開來，需要持續進行醫生教育，並提供強力的對比臨床試驗證據。監管機構在區分食品級和藥品級微生物組干預措施方面也面臨定義上的挑戰，這造成了合規性方面的模糊不清，並使市場定位變得更加複雜。

新冠疫情的影響：

針對新冠病毒的研究揭示了腸道菌群紊亂與新冠病毒感染的嚴重程度以及長期新冠症狀的持續存在之間存在顯著關聯，這極大地提升了科學界和投資者對基於微生物組的治療性介入的興趣。疫情期間開展的旨在評估微生物組調控以增強呼吸道感染疾病抵抗力的研究項目，拓展了治療應用範圍。疫情後對微生物組研究的投資以及監管力道的加大，縮短了關鍵生物醫學候選產品的研發週期。

在預測期內，生物醫學產品（LBP）細分市場預計將佔據最大的市場佔有率。

預計在預測期內，生物製藥（LBP）領域將佔據最大的市場佔有率。這是因為FDA和EMA已將生物製藥認定為具有明確監管路徑的獨特藥物類別，從而能夠進行有價值的臨床開發項目。目前，針對艱難梭菌感染疾病、發炎性腸道疾病和腫瘤適應症的多個LBP候選藥物正處於II期和III期臨床試驗階段。與普通益生菌相比，生物製藥具有明顯的臨床差異，且醫保報銷前景良好，這些因素正吸引製藥業持續投資該領域。

在預測期內，口腔市場預計將呈現最高的複合年成長率。

在預測期內，口服製劑市場預計將呈現最高的成長率。這主要得益於患者對非侵入性給藥方式的偏好，以及製藥業對新一代包封技術的投資，這些技術能夠保護活性微生物製劑免受胃酸分解。口服給藥方式使得門診病人可以自行給藥，顯著擴大了目標患者群體，使其不再局限於醫院進行的糞便微生物移植（FMT）手術。腸溶衣技術和產孢微生物製劑的進步正在改善口服活性微生物製劑的臨床療效，並有助於與監管機構更好地合作，從而支持產品核可。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這主要得益於美國食品藥物管理局 (FDA) 在建立生物醫學產品核准框架方面的監管主導地位、微生物組生物技術公司的集中以及該領域的大量創業投資投資。美國擁有全球最高的處於臨床階段的微生物組治療項目密度。胃腸道疾病的高發生率、完善的專科藥物報銷體係以及領先的微生物組學術研究機構的存在，共同支撐了北美商業生態系統的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、日本和韓國生物技術投資的不斷成長、人們對腸道健康療法的日益關注，以及大量胃腸道疾病患者。亞太地區各國政府資助的微生物組研究舉措正在建構臨床試驗基礎設施和監管合規能力，吸引國際製藥公司合作。由於益生菌和發酵食品在當地文化中根深蒂固，消費者對基於微生物組的治療理念接受度較高，這加速了處方藥的普及。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球微生物組療法市場：依產品類型分類

  • 益生菌類治療藥物
    • 單菌株益生菌
    • 多菌株益生菌
    • 新一代益生菌
  • 益生元療法
    • 寡糖
    • 膳食纖維
  • 合益素
  • 糞便微生物移植（FMT）
  • 生物醫學產品（LBPs）

第6章：全球微生物組療法市場：依給藥途徑分類

  • 口服
  • 直腸
  • 局部的
  • 其他

第7章 全球微生物組療法市場：依技術分類

  • 微生物組定序技術
  • 總體基因體學和生物資訊學
  • 微生物基因工程
  • 藥物傳輸技術
  • 人工智慧驅動的微生物組分析

第8章 全球微生物組療法市場：依應用分類

  • 消化系統疾病
    • 發炎性腸道疾病（IBD）
    • 大腸激躁症（IBS）
  • 代謝性疾病
    • 肥胖
    • 糖尿病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第9章：全球微生物組療法市場：依最終用戶分類

  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構
  • 受託研究機構
  • 其他最終用戶

第10章 全球微生物組療法市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • Enterome
  • Second Genome
  • Rebiotix
  • 4D Pharma
  • Vedanta Biosciences
  • Synlogic
  • BiomeBank
  • Yakult Honsha
  • Nestle Health Science
  • Danone
  • DuPont（IFF）
  • Probi AB
  • Chr. Hansen
  • Novozymes
  • Optibiotix Health
  • Evelo Biosciences
Product Code: SMRC34769

According to Stratistics MRC, the Global Microbiome Therapeutics Market is accounted for $9.6 billion in 2026 and is expected to reach $31.2 billion by 2034 growing at a CAGR of 15.8% during the forecast period. Microbiome therapeutics refer to biological interventions designed to modulate the composition and function of the human microbiome the complex community of microorganisms inhabiting the gut, skin, respiratory tract, and other body sites to prevent, treat, or manage disease conditions. They encompass live biotherapeutic products, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation formulations. These therapeutics target inflammatory bowel disease, Clostridioides difficile infections, metabolic disorders, oncology indications, and neuropsychiatric conditions by restoring dysbiotic microbial ecosystems.

Market Dynamics:

Driver:

Rising Gut Disorder Prevalence

Rising global prevalence of inflammatory bowel disease, irritable bowel syndrome, and Clostridioides difficile infections is a primary driver compelling pharmaceutical investment in microbiome therapeutic solutions. Conventional antibiotic and immunosuppressive treatment limitations create unmet clinical needs that microbiome-based interventions are positioned to address with disease-modifying rather than symptom-suppressing mechanisms. FDA approval frameworks for live biotherapeutic products are maturing, accelerating commercial pipeline investment and generating late-stage clinical programs across major gastrointestinal and systemic disease indications.

Restraint:

Manufacturing Standardization Complexity

Manufacturing standardization complexity represents a critical barrier as live biotherapeutic products and fecal microbiota transplantation formulations require consistent microbial community composition across production batches - a challenge that current GMP frameworks and quality control assay infrastructure are still evolving to address. Strain viability maintenance during manufacturing, formulation, and cold-chain distribution imposes substantial operational complexity. Regulatory divergence between the United States, Europe, and Asia Pacific on live biotherapeutic product classification creates parallel submission burdens that disproportionately impact smaller microbiome therapeutic developers.

Opportunity:

Oncology Microbiome Modulation

Oncology microbiome modulation presents a transformative commercial opportunity as clinical evidence accumulates demonstrating that gut microbiome composition significantly influences cancer immunotherapy response rates and treatment toxicity profiles. Live biotherapeutic products designed to optimize anti-tumor immune responses in combination with checkpoint inhibitor regimens are generating compelling early clinical data. Pharmaceutical companies are forming strategic partnerships with microbiome platform developers to incorporate microbiome modulation as a standard component of cancer immunotherapy protocols across melanoma, lung cancer, and other solid tumor indications.

Threat:

Competitive Probiotic Consumer Products

Competitive pricing pressure from consumer probiotic products creates a reimbursement and positioning challenge for clinical microbiome therapeutics, as physicians and patients may perceive commercial probiotic supplements as equivalent alternatives to prescription-grade live biotherapeutic products at substantially lower cost. Differentiating clinical-grade microbiome therapeutics from consumer wellness products requires sustained physician education investment and robust comparative clinical trial evidence. Regulatory agencies face definitional challenges distinguishing food-grade from drug-grade microbiome interventions, creating compliance ambiguity that complicates market positioning.

Covid-19 Impact:

COVID-19 research identified significant associations between gut microbiome dysbiosis and COVID-19 disease severity and long-COVID symptom persistence, generating substantial scientific and investor interest in microbiome therapeutic interventions. Pandemic-era research programs evaluating microbiome modulation for respiratory infection resilience have expanded the recognized therapeutic application scope. Post-pandemic, accelerated microbiome research investment and regulatory agency engagement have shortened development timelines for leading live biotherapeutic product candidates.

The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period

The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, due to FDA and EMA recognition of LBPs as a distinct pharmaceutical category with defined regulatory pathways, enabling investment-grade clinical development programs. Multiple LBP candidates addressing C. difficile infection, inflammatory bowel disease, and oncology indications are in Phase II and Phase III clinical stages. Strong clinical evidence differentiation from general probiotics and clear reimbursement pathway visibility are attracting sustained pharmaceutical industry investment in the segment.

The oral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oral segment is predicted to witness the highest growth rate, driven by patient preference for non-invasive delivery formats and pharmaceutical investment in next-generation encapsulation technologies that protect live microbiome formulations from gastric acid degradation. Oral delivery enables outpatient self-administration, substantially expanding addressable patient populations beyond hospital-administered fecal microbiota transplantation procedures. Advancements in enteric coating technologies and spore-forming organism formulations are improving oral LBP clinical performance, generating positive regulatory interactions supporting product approvals.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to FDA regulatory leadership in establishing live biotherapeutic product approval frameworks, concentration of microbiome biotechnology companies, and substantial venture capital investment in the sector. The United States hosts the highest density of clinical-stage microbiome therapeutic programs globally. High gastrointestinal disease prevalence, well-developed specialty pharmaceutical reimbursement infrastructure, and leading academic microbiome research institutions sustain North America's commercial ecosystem dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding biotechnology investment in China, Japan, and South Korea, growing awareness of gut health therapeutics, and large patient populations with gastrointestinal disorders. Government-funded microbiome research initiatives across Asia Pacific are building clinical trial infrastructure and regulatory competency that are attracting international pharmaceutical partnerships. Cultural integration of probiotic and fermented food traditions creates consumer openness to microbiome-based therapeutic concepts that accelerates prescription adoption.

Key players in the market

Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Ferring Pharmaceuticals, Enterome, Second Genome, Rebiotix, 4D Pharma, Vedanta Biosciences, Synlogic, BiomeBank, Yakult Honsha, Nestle Health Science, Danone, DuPont (IFF), Probi AB, Chr. Hansen, Novozymes, Optibiotix Health, and Evelo Biosciences.

Key Developments:

In March 2026, Seres Therapeutics initiated a Phase II combination study evaluating its microbiome therapeutic alongside pembrolizumab for solid tumor indications including non-small cell lung cancer.

In February 2026, Synlogic advanced its engineered probiotic candidate for phenylketonuria into Phase III pivotal trials following positive interim metabolic control endpoint data.

In January 2026, Ferring Pharmaceuticals received expanded FDA approval for its live biotherapeutic product REBYOTA covering additional C. difficile recurrence prevention indications in immunocompromised patients.

In November 2025, Vedanta Biosciences reported positive Phase II efficacy data for its defined bacterial consortium LBP targeting ulcerative colitis remission induction in moderate-to-severe patients.

Product Types Covered:

  • Probiotics-based Therapeutics
  • Prebiotics-based Therapeutics
  • Synbiotics
  • Fecal Microbiota Transplantation (FMT)
  • Live Biotherapeutic Products (LBPs)

Route of Administrations Covered:

  • Oral
  • Rectal
  • Topical
  • Others

Technologies Covered:

  • Microbiome Sequencing Technologies
  • Metagenomics & Bioinformatics
  • Genetic Engineering of Microbes
  • Drug Delivery Technologies
  • AI-driven Microbiome Analysis

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Oncology

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Other End Userz

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microbiome Therapeutics Market, By Product Type

  • 5.1 Probiotics-based Therapeutics
    • 5.1.1 Single-Strain Probiotics
    • 5.1.2 Multi-Strain Probiotics
    • 5.1.3 Next-Generation Probiotics
  • 5.2 Prebiotics-based Therapeutics
    • 5.2.1 Oligosaccharides
    • 5.2.2 Dietary Fibers
  • 5.3 Synbiotics
  • 5.4 Fecal Microbiota Transplantation (FMT)
  • 5.5 Live Biotherapeutic Products (LBPs)

6 Global Microbiome Therapeutics Market, By Route of Administration

  • 6.1 Oral
  • 6.2 Rectal
  • 6.3 Topical
  • 6.4 Others

7 Global Microbiome Therapeutics Market, By Technology

  • 7.1 Microbiome Sequencing Technologies
  • 7.2 Metagenomics & Bioinformatics
  • 7.3 Genetic Engineering of Microbes
  • 7.4 Drug Delivery Technologies
  • 7.5 AI-driven Microbiome Analysis

8 Global Microbiome Therapeutics Market, By Application

  • 8.1 Gastrointestinal Disorders
    • 8.1.1 Inflammatory Bowel Disease (IBD)
    • 8.1.2 Irritable Bowel Syndrome (IBS)
  • 8.2 Metabolic Disorders
    • 8.2.1 Obesity
    • 8.2.2 Diabetes
  • 8.3 Infectious Diseases
  • 8.4 Neurological Disorders
  • 8.5 Oncology

9 Global Microbiome Therapeutics Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Research Institutes
  • 9.4 Contract Research Organizations
  • 9.5 Other End Userz

10 Global Microbiome Therapeutics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Ferring Pharmaceuticals
  • 12.3 Enterome
  • 12.4 Second Genome
  • 12.5 Rebiotix
  • 12.6 4D Pharma
  • 12.7 Vedanta Biosciences
  • 12.8 Synlogic
  • 12.9 BiomeBank
  • 12.10 Yakult Honsha
  • 12.11 Nestle Health Science
  • 12.12 Danone
  • 12.13 DuPont (IFF)
  • 12.14 Probi AB
  • 12.15 Chr. Hansen
  • 12.16 Novozymes
  • 12.17 Optibiotix Health
  • 12.18 Evelo Biosciences

List of Tables

  • Table 1 Global Microbiome Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Microbiome Therapeutics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Microbiome Therapeutics Market Outlook, By Probiotics-based Therapeutics (2023-2034) ($MN)
  • Table 4 Global Microbiome Therapeutics Market Outlook, By Single-Strain Probiotics (2023-2034) ($MN)
  • Table 5 Global Microbiome Therapeutics Market Outlook, By Multi-Strain Probiotics (2023-2034) ($MN)
  • Table 6 Global Microbiome Therapeutics Market Outlook, By Next-Generation Probiotics (2023-2034) ($MN)
  • Table 7 Global Microbiome Therapeutics Market Outlook, By Prebiotics-based Therapeutics (2023-2034) ($MN)
  • Table 8 Global Microbiome Therapeutics Market Outlook, By Oligosaccharides (2023-2034) ($MN)
  • Table 9 Global Microbiome Therapeutics Market Outlook, By Dietary Fibers (2023-2034) ($MN)
  • Table 10 Global Microbiome Therapeutics Market Outlook, By Synbiotics (2023-2034) ($MN)
  • Table 11 Global Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplantation (FMT) (2023-2034) ($MN)
  • Table 12 Global Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (LBPs) (2023-2034) ($MN)
  • Table 13 Global Microbiome Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 14 Global Microbiome Therapeutics Market Outlook, By Oral (2023-2034) ($MN)
  • Table 15 Global Microbiome Therapeutics Market Outlook, By Rectal (2023-2034) ($MN)
  • Table 16 Global Microbiome Therapeutics Market Outlook, By Topical (2023-2034) ($MN)
  • Table 17 Global Microbiome Therapeutics Market Outlook, By Others (2023-2034) ($MN)
  • Table 18 Global Microbiome Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Microbiome Therapeutics Market Outlook, By Microbiome Sequencing Technologies (2023-2034) ($MN)
  • Table 20 Global Microbiome Therapeutics Market Outlook, By Metagenomics & Bioinformatics (2023-2034) ($MN)
  • Table 21 Global Microbiome Therapeutics Market Outlook, By Genetic Engineering of Microbes (2023-2034) ($MN)
  • Table 22 Global Microbiome Therapeutics Market Outlook, By Drug Delivery Technologies (2023-2034) ($MN)
  • Table 23 Global Microbiome Therapeutics Market Outlook, By AI-driven Microbiome Analysis (2023-2034) ($MN)
  • Table 24 Global Microbiome Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 25 Global Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 26 Global Microbiome Therapeutics Market Outlook, By Inflammatory Bowel Disease (IBD) (2023-2034) ($MN)
  • Table 27 Global Microbiome Therapeutics Market Outlook, By Irritable Bowel Syndrome (IBS) (2023-2034) ($MN)
  • Table 28 Global Microbiome Therapeutics Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 29 Global Microbiome Therapeutics Market Outlook, By Obesity (2023-2034) ($MN)
  • Table 30 Global Microbiome Therapeutics Market Outlook, By Diabetes (2023-2034) ($MN)
  • Table 31 Global Microbiome Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 32 Global Microbiome Therapeutics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 33 Global Microbiome Therapeutics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 34 Global Microbiome Therapeutics Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Microbiome Therapeutics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 36 Global Microbiome Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 37 Global Microbiome Therapeutics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 38 Global Microbiome Therapeutics Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 39 Global Microbiome Therapeutics Market Outlook, By Other End Userz (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.